About: Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
Creator	Liu, Xiao Chen, \| Hong, Kui Kui, \| Long, Chuyan Ma, Jianyong Su, Yuhao Xiong, Qinmei
Source	Medline; PMC
abstract	An association among the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin‐receptor blockers (ARBs) with the clinical outcomes of coronavirus disease 2019 (COVID‐19) is unclear. PubMed, EMBASE, MedRxiv, and BioRxiv were searched for relevant studies that assessed the association between application of ACEI/ARB and risk of COVID‐19, inflammation level, severity COVID‐19 infection, and death in patients with COVID‐19. Eleven studies were included with 33 483 patients. ACEI/ARB therapy might be associated with the reduced inflammatory factor (interleukin‐6) and elevated immune cells counts (CD3, CD8). Meta‐analysis showed no significant increase in the risk of COVID‐19 infection (odds ratio [OR]: 0.95, 95%CI: 0.89‐1.05) in patients receiving ACEI/ARB therapy, and ACEI/ARB therapy was associated with a decreased risk of severe COVID‐19 (OR: 0.75, 95%CI: 0.59‐0.96) and mortality (OR: 0.52, 95%CI: 0.35‐0.79). Subgroup analyses showed among the general population, ACEI/ARB therapy was associated with reduced severe COVID‐19 infection (OR: 0.79, 95%CI: 0.60‐1.05) and all‐cause mortality (OR: 0.31, 95%CI: 0.13‐0.75), and COVID‐19 infection (OR: 0.85, 95% CI: 0.66‐1.08) were not increased. Among patients with hypertension, the use of an ACEI/ARB was associated with a lower severity of COVID‐19 (OR: 0.73, 95%CI: 0.51‐1.03) and lower mortality (OR: 0.57, 95%CI: 0.37‐0.87), without evidence of an increased risk of COVID‐19 infection (OR: 1.00). On the basis of the available evidence, ACEI/ARB therapy should be continued in patients who are at risk for, or have COVID‐19, either in general population or hypertension patients. Our results need to be interpreted with caution considering the potential for residual confounders, and more well‐designed studies that control the clinical confounders are necessary to confirm our findings.
has issue date	2020-08-05(xsd:dateTime)
bibo:doi	10.1002/clc.23421
bibo:pmid	32757246
has license	cc-by
sha1sum (hex)	085096709188fc556f729e600ee60a5a9efbffc0
schema:url	https://doi.org/10.1002/clc.23421
resource representing a document's title	Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID‐19, inflammation level, severity, and death in patients with COVID‐19: A rapid systematic review and meta‐analysis
has PubMed Central identifier	PMC7436520
has PubMed identifier	32757246
schema:publication	Clin Cardiol
resource representing a document's body	covid:085096709188fc556f729e600ee60a5a9efbffc0#body_text
is schema:about of	named entity 'level' named entity 'infection' named entity 'studies' named entity 'evidence' named entity 'severe' named entity 'odds ratio' named entity 'PubMed' named entity 'inhibitors' named entity 'angiotensin' named entity 'converting' named entity 'blockers' named entity 'HYPERTENSION' named entity 'INCREASED' named entity 'STUDIES' named entity 'EVIDENCE OF' named entity 'USE OF' named entity 'ALL-CAUSE MORTALITY' covid:arg/085096709188fc556f729e600ee60a5a9efbffc0 named entity 'reduced' named entity 'patients' named entity 'mortality' named entity 'infection' named entity 'coronavirus disease 2019' named entity 'ACE' named entity 'risk' named entity 'COVID-19' named entity 'COVID' named entity 'EMBASE' named entity 'ACEI' named entity 'CD3' named entity 'Meta-analysis' named entity 'ACEI' named entity '1.08' named entity 'COVID' named entity 'coronavirus disease 2019' named entity 'receptor' named entity 'inflammation' named entity 'meta-analysis' named entity 'angiotensin II receptor blockers' named entity 'infection' named entity 'COVID-19' named entity 'prognosis' named entity 'COVID-19' named entity 'RAAS' named entity 'medRxiv' named entity 'ACEI' named entity 'ARBs' named entity 'inflammation' named entity 'meta-analysis' named entity 'AT1R' named entity 'RAAS' named entity 'COVID' named entity 'downregulating' named entity 'SARS-CoV' named entity 'public health' named entity 'Angiotensin II receptor' named entity 'sensitivity analysis' named entity 'follow-up' named entity 'meta-analysis' named entity 'cardiovascular diseases' named entity 'Embase' named entity 'randomized controlled trial' named entity 'inflammation' named entity 'COVID' named entity 'COVID' named entity 'multiorgan dysfunction' named entity 'COVID' named entity 'EMBASE' named entity 'controlled clinical trial' named entity 'ACEIs' named entity 'COVID-19' named entity 'infection' named entity 'SARS-CoV-2' named entity 'recall bias'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software